Lindsay A. Rosenwald, M.D. – Executive Chairman
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as Caelum’s Executive Chairman, Dr. Rosenwald is Chairman, President and CEO of Fortress Biotech, Caelum’s parent company. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.
Michael Spector – President and Chief Executive Officer
Mr. Spector was named President and Chief Executive Officer of Caelum and a member of the board of directors in January 2017. He joins Caelum from Fortress Biotech, where he leveraged more than 25 years of biotechnology experience to identify emerging and innovative technologies to launch as new biotech and specialty pharmaceutical companies. Prior to Fortress, Mr. Spector served as Senior Vice President, Global Commercial Operations at Iroko Pharmaceuticals. Earlier in his career, he spent 15 years at GlaxoSmithKline in multiple senior management positions, including Vice President and General Manager of GlaxoSmithKline South Africa, where he led the overall business strategy and was elected to run the South African Pharmaceutical Manufacturers Association. Mr. Spector is also a founding member of Windhoek Healthcare, where he launched two specialty pharmaceutical companies: Laurel Pharmaceuticals and North Creek Pharmaceuticals. Mr. Spector holds an M.B.A. from Rider University in Lawrenceville, N.J., where he serves on the Business and Scientific Advisory Boards, and a B.S. in biology from the University of Pittsburgh. He also serves on the Board of Directors of Jacaranda Health, a nonprofit organization that seeks to transform maternal and neonatal healthcare in East Africa.
Elisabeth Leiderman, M.D., M.B.A. – Vice President, Corporate Development
Dr. Leiderman has 20 years of experience working in the healthcare industry. Since January 2017, Dr. Leiderman has served as Vice President and Head of Corporate Development at Caelum which is a subsidiary of Fortress Biotech. Prior to joining industry, Dr. Leiderman worked as a Healthcare Investment Banker, where she most recently was an Executive Director at Nomura Securities. She spent close to 10 years on Wall Street and held prior roles at UBS and Credit Suisse. She has covered life science companies and advised clients on M&A, Equity and Debt transactions. Dr. Leiderman earned her B.A. at The University of Pennsylvania, her M.D. from Sackler Medical School at Tel-Aviv University and her MBA from The Wharton School. Dr. Leiderman is an employee of Fortress Biotech and provides services to Caelum Biosciences pursuant to a Management Services Agreement between Fortress Biotech and Caelum Biosciences.